AKAO News and Press, Achaogen

Antibiotics maker, Paratek Pharmaceuticals ( PRTK ), has struggled to hold onto gains in 2019. The has been a recent setback in the clinic but success on the funding front, both of which are worth discussing and the first focus of this article. Secondly, I look forward to a potential catalys...

Recently in the journal Nature , an article was published characterizing the oldest known example of a fungus. The organism, termed an Ourasphaira, was approximately one billion years old and was found in what was believed to be an ancient river bed in Canada. For comparison sake, the oldes...

SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substan...

Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett Writing about antibiotic innovators is a quandary for me because I have to balance between the need for investment profits for investors vs. my social responsibility. It's an inte...

Antibiotic resistance is a growing global public health emergency. Melinta Therapeutics ( MLNT ) has decided to take up the critical mission of overcoming antibiotic resistance with their broad spectrum antibiotic portfolio. Unfortunately, the market doesn’t see the opportunity in addre...

Longs in nano cap Achaogen (NASDAQ: AKAO ) are facing a near-total wipeout this morning on the news that it has filed for Chapter 11 bankruptcy protection. More news on: Achaogen, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a volun...

Achaogen, Inc. (AKAO) Q4 2018 Earnings Conference Call March 28, 2019 4:30 PM ET Company Participants Gary Loeb - General Counsel and Chief Compliance Officer Blake Wise - Chief Executive Officer Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - Chief Financial Officer...

Achaogen (NASDAQ: AKAO ): Q4 GAAP EPS of -$1.01 misses by $0.26 . More news on: Achaogen, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference call today at 4:30 p.m. Eastern Time -- SOUTH S...